Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis

Gastroenterology

Volumn 146, Issue 1, 2014, Pages

  Sandborn, William J ^a   Feagan, Brian G ^b   Marano, Colleen ^c   Zhang, Hongyan ^c   Strauss, Richard ^c   Johanns, Jewel ^c   Adedokun, Omoniyi J ^c   Guzzo, Cynthia ^d   Colombel, Jean Frederic ^e,f   Reinisch, Walter ^g   Gibson, Peter R ^h   Collins, Judith ⁱ   Järnerot, Gunnar ^j   Rutgeerts, Paul ^k  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d Janssen Services LLC   (United States)

^e UNIV LILLE   (France)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h MONASH UNIVERSITY   (Australia)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^j ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^k UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

Fully Human Monoclonal Antibody; Inflammatory Bowel Disease; Randomized Withdrawal Trial

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID DERIVATIVE; GOLIMUMAB; ISONIAZID; MERCAPTOPURINE; MESALAZINE; PLACEBO; PREDNISONE;

ABDOMINAL PAIN; ADULT; ADULT DISEASE; ANAPHYLAXIS; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; COUGHING; CYST; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENDOSCOPY; FEMALE; HEALING; HEART FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE REACTION; LATENT TUBERCULOSIS; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MILIARY TUBERCULOSIS; OPPORTUNISTIC INFECTION; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POLYP; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REMISSION; RHINOPHARYNGITIS; SEPSIS; SUBCUTANEOUS IMMUNOTHERAPY; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 84890629055     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2013.06.010     Document Type: Article

References (22)

1. I. Ordás, L. Eckmann, and M. Talamini Ulcerative colitis Lancet 380 2012 1606 1619
2. E. Langholz, P. Munkholm, and M. Davidsen Course of ulcerative colitis: analysis of changes in disease activity over years Gastroenterology 107 1994 3 11
3. O. Hoie, F.L. Wolters, L. Riis on behalf of the European Collaborative Study Group of Inflammatory Bowel Disease Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years Gastroenterology 132 2007 507 515
4. A. Aratari, C. Papi, and V. Clemente Colectomy rate in acute severe ulcerative colitis in the infliximab era Dig Liver Dis 40 2008 821 826
5. J. Filippi, P.B. Allen, and X. Hébuterne Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review Curr Drug Targets 12 2011 1440 1447
6. P. Rutgeerts, W.J. Sandborn, and B.G. Feagan Infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med 353 2005 2462 2476
7. W. Reinisch, W.J. Sandborn, and D.W. Hommes Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial Gut 60 2011 780 787
8. W.J. Sandborn, G. van Assche, and W. Reinisch Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis Gastroenterology 142 2012 257 265.e1-3
9. D. Shealy, A. Cai, and K. Staquet Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α MAbs 2 2010 428 439
10. J. Kay, E.L. Matteson, and B. Dasgupta Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study Arthritis Rheum 58 2008 964 975
11. E.C. Keystone, M.C. Genovese, and L. Klareskog Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study Ann Rheum Dis 69 2010 1129 1135
12. P. Emery, R.M. Fleischmann, and L.W. Moreland Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis Arthritis Rheum 60 2009 2272 2283
13. J.S. Smolen, J. Kay, M.K. Doyle for the GO-AFTER study investigators Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial Lancet 374 2009 210 221
14. J. Braun, A. Deodhar, and R.D. Inman Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study Ann Rheum Dis 71 2012 661 667
15. A. Kavanaugh, D. van der Heijde, and I.B. McInnes Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial Arthritis Rheum 64 2012 2504 2517
16. K.W. Schroeder, W.J. Tremaine, and D.M. Ilstrup Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study N Engl J Med 317 1987 1625 1629
17. G. D'Haens, W.J. Sandborn, and B.G. Feagan A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis Gastroenterology 132 2007 763 786
18. W.J. Sandborn, B.G. Feagan, C. Marano for the PURSUIT-SC study group Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis Gastroenterology 2013 10.1053/j.gastro. 2013.05.048 [Epub ahead of print].
19. Y. Zhuang, Z. Xu, and B. Frederick Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study Clin Ther 34 2012 77 90
20. H. Zhou, H. Jang, and R.M. Fleischmann Pharmacokinetics and safety of golimumab, a fully human anti-TNF-α monoclonal antibody, in subjects with rheumatoid arthritis J Clin Pharmacol 47 2007 383 396
21. I. Ordás, B.G. Feagan, and W.J. Sandborn Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease Clin Gastroenterol Hepatol 10 2012 1079 1087
22. Simponi Package insert 2011 Janssen Biotech, Inc Horsham, PA